CompletedNCT05721235
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
Medication studyAges 4–5United States
Understand this study
Who was this study for?
Listed age limits: 4 years to 5 years.
- Listed locations
- Little Rock and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: June 2, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 123
- Sponsor
- Corium, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 4 Years to 5 Years
- Official registry ID
- NCT05721235
- Official title
Show the full official title
A Multicenter, Dose-Optimized, Open-Label, Safety/Tolerability and Pharmacokinetic Study With Azstarys® in Children 4 and 5 Years of Age With Attention-Deficit/Hyperactivity Disorder
Recruitment & locations
CompletedLittle Rock · Anaheim · Centennial
17 more locations
- Jacksonville
- Lakeland
- Maitland
- Miami Springs
- Orlando
- Decatur
- Savannah
- Union City
- New Orleans
- Saint Charles
- Missoula
- Lincoln
- Las Vegas
- Memphis
- Bellaire
- Plano
- San Antonio
Questions about this study
Who is behind this study?
The study sponsor is Corium, Inc.
Did this study involve medication?
Yes. The study involved medication, including Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH).
Who was this study for?
Listed age limits: 4 years to 5 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)